Cargando…
Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients
BACKGROUND: Autoimmune Polyglandular Syndrome type 1 (APS-1) is a rare recessive inherited disease, caused by AutoImmune Regulator (AIRE) gene mutations and characterized by three major manifestations: chronic mucocutaneous candidiasis (CMC), chronic hypoparathyroidism (CH) and Addison’s disease (AD...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502131/ https://www.ncbi.nlm.nih.gov/pubmed/34003463 http://dx.doi.org/10.1007/s40618-021-01585-6 |
_version_ | 1784580820972863488 |
---|---|
author | Garelli, S. Dalla Costa, M. Sabbadin, C. Barollo, S. Rubin, B. Scarpa, R. Masiero, S. Fierabracci, A. Bizzarri, C. Crinò, A. Cappa, M. Valenzise, M. Meloni, A. De Bellis, A. M. Giordano, C. Presotto, F. Perniola, R. Capalbo, D. Salerno, M. C. Stigliano, A. Radetti, G. Camozzi, V. Greggio, N. A. Bogazzi, F. Chiodini, I. Pagotto, U. Black, S. K. Chen, S. Rees Smith, B. Furmaniak, J. Weber, G. Pigliaru, F. De Sanctis, L. Scaroni, C. Betterle, C. |
author_facet | Garelli, S. Dalla Costa, M. Sabbadin, C. Barollo, S. Rubin, B. Scarpa, R. Masiero, S. Fierabracci, A. Bizzarri, C. Crinò, A. Cappa, M. Valenzise, M. Meloni, A. De Bellis, A. M. Giordano, C. Presotto, F. Perniola, R. Capalbo, D. Salerno, M. C. Stigliano, A. Radetti, G. Camozzi, V. Greggio, N. A. Bogazzi, F. Chiodini, I. Pagotto, U. Black, S. K. Chen, S. Rees Smith, B. Furmaniak, J. Weber, G. Pigliaru, F. De Sanctis, L. Scaroni, C. Betterle, C. |
author_sort | Garelli, S. |
collection | PubMed |
description | BACKGROUND: Autoimmune Polyglandular Syndrome type 1 (APS-1) is a rare recessive inherited disease, caused by AutoImmune Regulator (AIRE) gene mutations and characterized by three major manifestations: chronic mucocutaneous candidiasis (CMC), chronic hypoparathyroidism (CH) and Addison’s disease (AD). METHODS: Autoimmune conditions and associated autoantibodies (Abs) were analyzed in 158 Italian patients (103 females and 55 males; F/M 1.9/1) at the onset and during a follow-up of 23.7 ± 15.1 years. AIRE mutations were determined. RESULTS: The prevalence of APS-1 was 2.6 cases/million (range 0.5–17 in different regions). At the onset 93% of patients presented with one or more components of the classical triad and 7% with other components. At the end of follow-up, 86.1% had CH, 77.2% AD, 74.7% CMC, 49.5% premature menopause, 29.7% autoimmune intestinal dysfunction, 27.8% autoimmune thyroid diseases, 25.9% autoimmune gastritis/pernicious anemia, 25.3% ectodermal dystrophy, 24% alopecia, 21.5% autoimmune hepatitis, 17% vitiligo, 13.3% cholelithiasis, 5.7% connective diseases, 4.4% asplenia, 2.5% celiac disease and 13.9% cancer. Overall, 991 diseases (6.3 diseases/patient) were found. Interferon-ω Abs (IFNωAbs) were positive in 91.1% of patients. Overall mortality was 14.6%. The AIRE mutation R139X was found in 21.3% of tested alleles, R257X in 11.8%, W78R in 11.4%, C322fsX372 in 8.8%, T16M in 6.2%, R203X in 4%, and A21V in 2.9%. Less frequent mutations were present in 12.9%, very rare in 9.6% while no mutations in 11% of the cases. CONCLUSIONS: In Italy, APS-1 is a rare disorder presenting with the three major manifestations and associated with different AIRE gene mutations. IFNωAbs are markers of APS-1 and other organ-specific autoantibodies are markers of clinical, subclinical or potential autoimmune conditions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40618-021-01585-6. |
format | Online Article Text |
id | pubmed-8502131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-85021312021-10-22 Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients Garelli, S. Dalla Costa, M. Sabbadin, C. Barollo, S. Rubin, B. Scarpa, R. Masiero, S. Fierabracci, A. Bizzarri, C. Crinò, A. Cappa, M. Valenzise, M. Meloni, A. De Bellis, A. M. Giordano, C. Presotto, F. Perniola, R. Capalbo, D. Salerno, M. C. Stigliano, A. Radetti, G. Camozzi, V. Greggio, N. A. Bogazzi, F. Chiodini, I. Pagotto, U. Black, S. K. Chen, S. Rees Smith, B. Furmaniak, J. Weber, G. Pigliaru, F. De Sanctis, L. Scaroni, C. Betterle, C. J Endocrinol Invest Original Article BACKGROUND: Autoimmune Polyglandular Syndrome type 1 (APS-1) is a rare recessive inherited disease, caused by AutoImmune Regulator (AIRE) gene mutations and characterized by three major manifestations: chronic mucocutaneous candidiasis (CMC), chronic hypoparathyroidism (CH) and Addison’s disease (AD). METHODS: Autoimmune conditions and associated autoantibodies (Abs) were analyzed in 158 Italian patients (103 females and 55 males; F/M 1.9/1) at the onset and during a follow-up of 23.7 ± 15.1 years. AIRE mutations were determined. RESULTS: The prevalence of APS-1 was 2.6 cases/million (range 0.5–17 in different regions). At the onset 93% of patients presented with one or more components of the classical triad and 7% with other components. At the end of follow-up, 86.1% had CH, 77.2% AD, 74.7% CMC, 49.5% premature menopause, 29.7% autoimmune intestinal dysfunction, 27.8% autoimmune thyroid diseases, 25.9% autoimmune gastritis/pernicious anemia, 25.3% ectodermal dystrophy, 24% alopecia, 21.5% autoimmune hepatitis, 17% vitiligo, 13.3% cholelithiasis, 5.7% connective diseases, 4.4% asplenia, 2.5% celiac disease and 13.9% cancer. Overall, 991 diseases (6.3 diseases/patient) were found. Interferon-ω Abs (IFNωAbs) were positive in 91.1% of patients. Overall mortality was 14.6%. The AIRE mutation R139X was found in 21.3% of tested alleles, R257X in 11.8%, W78R in 11.4%, C322fsX372 in 8.8%, T16M in 6.2%, R203X in 4%, and A21V in 2.9%. Less frequent mutations were present in 12.9%, very rare in 9.6% while no mutations in 11% of the cases. CONCLUSIONS: In Italy, APS-1 is a rare disorder presenting with the three major manifestations and associated with different AIRE gene mutations. IFNωAbs are markers of APS-1 and other organ-specific autoantibodies are markers of clinical, subclinical or potential autoimmune conditions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40618-021-01585-6. Springer International Publishing 2021-05-18 2021 /pmc/articles/PMC8502131/ /pubmed/34003463 http://dx.doi.org/10.1007/s40618-021-01585-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Garelli, S. Dalla Costa, M. Sabbadin, C. Barollo, S. Rubin, B. Scarpa, R. Masiero, S. Fierabracci, A. Bizzarri, C. Crinò, A. Cappa, M. Valenzise, M. Meloni, A. De Bellis, A. M. Giordano, C. Presotto, F. Perniola, R. Capalbo, D. Salerno, M. C. Stigliano, A. Radetti, G. Camozzi, V. Greggio, N. A. Bogazzi, F. Chiodini, I. Pagotto, U. Black, S. K. Chen, S. Rees Smith, B. Furmaniak, J. Weber, G. Pigliaru, F. De Sanctis, L. Scaroni, C. Betterle, C. Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients |
title | Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients |
title_full | Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients |
title_fullStr | Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients |
title_full_unstemmed | Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients |
title_short | Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients |
title_sort | autoimmune polyendocrine syndrome type 1: an italian survey on 158 patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502131/ https://www.ncbi.nlm.nih.gov/pubmed/34003463 http://dx.doi.org/10.1007/s40618-021-01585-6 |
work_keys_str_mv | AT garellis autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT dallacostam autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT sabbadinc autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT barollos autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT rubinb autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT scarpar autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT masieros autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT fierabraccia autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT bizzarric autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT crinoa autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT cappam autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT valenzisem autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT melonia autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT debellisam autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT giordanoc autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT presottof autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT perniolar autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT capalbod autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT salernomc autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT stiglianoa autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT radettig autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT camozziv autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT greggiona autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT bogazzif autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT chiodinii autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT pagottou autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT blacksk autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT chens autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT reessmithb autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT furmaniakj autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT weberg autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT pigliaruf autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT desanctisl autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT scaronic autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients AT betterlec autoimmunepolyendocrinesyndrometype1anitaliansurveyon158patients |